Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy AbbVie stock
Learn how to easily invest in AbbVie stock.
AbbVie is a drug manufacturers-general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars. AbbVie employs 50,000 staff and has a trailing 12-month revenue of around $57.8 billion.
How to buy AbbVie stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ABBV. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
AbbVie stock price (NYSE: ABBV)Use our graph to track the performance of ABBV stocks over time.
AbbVie shares at a glance
|Latest market close||$147.79|
|52-week range||$128.17 - $169.46|
|50-day moving average||$158.81|
|200-day moving average||$149.99|
|Wall St. target price||$163.05|
|Dividend yield||$5.64 (3.99%)|
|Earnings per share (TTM)||$7.50|
Buy AbbVie stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AbbVie price performance over time
|1 week (2023-01-20)||-1.20%|
|1 month (2022-12-27)||-9.33%|
|3 months (2022-10-27)||-3.72%|
|6 months (2022-07-27)||-2.22%|
|1 year (2022-01-27)||8.69%|
|2 years (2021-01-27)||43.78%|
|3 years (2020-01-27)||75.90%|
|5 years (2018-01-26)||19.95%|
Is AbbVie stock undervalued or overvalued?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, AbbVie shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $29.8 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$57.8 billion|
|Operating margin TTM||37.21%|
|Gross profit TTM||$38.9 billion|
|Return on assets TTM||9.27%|
|Return on equity TTM||90.65%|
|Market capitalisation||$261.2 billion|
TTM: trailing 12 months
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||34.86|
|Total ESG percentile||65.78|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||3|
AbbVie share dividends
Dividend payout ratio: 42.3% of net profits
Recently AbbVie has paid out, on average, around 42.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.99% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.99% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $5.64 per share.
While AbbVie's payout ratio might seem fairly standard, it's worth remembering that AbbVie may be investing much of the rest of its net profits in future growth.
AbbVie's most recent dividend payout was on 14 February 2023. The latest dividend was paid out to all shareholders who bought their shares by 11 January 2023 (the "ex-dividend date").
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as $128.1711 up to $169.4595. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.624. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.
AbbVie in the news
12 Cheap Blue Chip Stocks To Buy
12 Cheap Biotech Stocks To Buy
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Frequently asked questionsWhat percentage of AbbVie is owned by insiders or institutions?
Currently 0.111% of AbbVie shares are held by insiders and 70.813% by institutions. How many people work for AbbVie?
Latest data suggests 50,000 work at AbbVie. When does the fiscal year end for AbbVie?
AbbVie's fiscal year ends in December. Where is AbbVie based?
AbbVie's address is: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 What is AbbVie's ISIN number?
AbbVie's international securities identification number is: US00287Y1091 What is AbbVie's CUSIP number?
AbbVie's Committee on Uniform Securities Identification Procedures number is: 00287T308
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert